This study is for adults with a type of blood cancer called Multiple Myeloma (MM), which has come back or not responded to treatment. It compares a new treatment, called arlo-cel (BMS-986393), with usual treatments. To join, you need to have had Relapsed or Refractory Multiple Myeloma (RRMM) and tried at least one but no more than three treatments before, including a drug named lenalidomide. The study checks if your organs work well and you feel strong enough to join (performance status 0 or 1).
Some people cannot join, like those with MM in the brain or who need urgent treatment. The main aim is to see if arlo-cel is better and safe compared to standard treatments for people who have been exposed to lenalidomide.
- Duration: The study details on how long it lasts aren't specified, but participants will be monitored closely.
- Visits: There will be multiple visits for treatment and check-ups.
- Risks: As with any treatment, there might be side effects, which will be monitored.
How understandable was the trial content above?
Hard to understand
Easy to understand